Fujifilm announced today as trading closed that it has acquired for approximately $800m two companies specialized in cultured cells, subsidiaries of Japanese holding JXTG. Specifically, the two companies are the California-based Irvine Scientific (ISUS) and the Japan-based IS Japan (ISJ), which will be included into the Fujifilm Diosynth Biotechnologies unit. Both companies provide biotech firms with culture media for in vitro fertilization and cell therapy. The companies successfully integrate, as Irvine Scientific distributes mainly in the U.S. and Europe, while IS Japan distributes mainly in Asia. Importantly, Fujifilm is already committed in regenerative medicine, which includes developing cultured cells and antibodies, and boasts an important position in the business, thanks to revenues of ¥432.5bn ($4.1 billion) in 2017.